A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma.

Trial Profile

A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 May 2017

At a glance

  • Drugs Lapuleucel T (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms Neu-ACT
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 21 Apr 2017 Status changed from completed to discontinued due to administrative reasons
    • 07 Jun 2016 Primary endpoint (overall survival rate) has not been met, according to a results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top